Medrx Co (TSE:4586) Beneish M-Score: -2.70 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4586 Medrx Co Ltd TSE:4586
57 GF Score
Price 円57.00
GF Value 円70.55
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medrx Co Beneish M-Score?

Medrx Co TSE:4586 +3.64% 57 Beneish M-Score is -2.70 as of Jul. 15, 2026. GuruFocus rates TSE:4586 with a GF Score™ of 57/100 and a GF Value™ of 円70.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Medrx Co ranks better than 68.06% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.7 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Medrx Co's Beneish M-Score or its related term are showing as below:

TSE:4586' s Beneish M-Score Range Over the Past 10 Years
Min: -2.7   Med: 2.66   Max: 19.62
Current: -2.7

During the past 13 years, the highest Beneish M-Score of Medrx Co was 19.62. The lowest was -2.70. And the median was 2.66.


Medrx Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Medrx Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medrx Co Beneish M-Score Chart

Medrx Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.48 1.83 0.18 3.52 -2.70

Medrx Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.52 0.00 0.00 -2.70 0.00

TSE:4586 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medrx Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medrx Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Medrx Co's Beneish M-Score falls into.


TSE:4586
57GF Score
Medrx Co Ltd TSE:4586
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medrx Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Medrx Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5824+0.528 * 1.0083+0.404 * 1.8692+0.892 * 0.4966+0.115 * 3.5218
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.022833-0.327 * 0.7718
=-2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was 円12.83 Mil.
Revenue was 円128.08 Mil.
Gross Profit was 円126.88 Mil.
Total Current Assets was 円1,824.96 Mil.
Total Assets was 円2,157.53 Mil.
Property, Plant and Equipment(Net PPE) was 円192.23 Mil.
Depreciation, Depletion and Amortization(DDA) was 円13.87 Mil.
Selling, General, & Admin. Expense(SGA) was 円0.00 Mil.
Total Current Liabilities was 円77.27 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.
Net Income was 円-937.37 Mil.
Gross Profit was 円0.00 Mil.
Cash Flow from Operations was 円-888.11 Mil.
Total Receivables was 円44.34 Mil.
Revenue was 円257.92 Mil.
Gross Profit was 円257.62 Mil.
Total Current Assets was 円2,072.74 Mil.
Total Assets was 円2,275.60 Mil.
Property, Plant and Equipment(Net PPE) was 円123.68 Mil.
Depreciation, Depletion and Amortization(DDA) was 円38.43 Mil.
Selling, General, & Admin. Expense(SGA) was 円0.00 Mil.
Total Current Liabilities was 円105.60 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(12.826 / 128.084) / (44.344 / 257.915)
=0.100137 / 0.171933
=0.5824

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(257.615 / 257.915) / (126.884 / 128.084)
=0.998837 / 0.990631
=1.0083

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1824.955 + 192.234) / 2157.533) / (1 - (2072.735 + 123.675) / 2275.6)
=0.065048 / 0.0348
=1.8692

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=128.084 / 257.915
=0.4966

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(38.427 / (38.427 + 123.675)) / (13.873 / (13.873 + 192.234))
=0.237054 / 0.06731
=3.5218

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 128.084) / (0 / 257.915)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 77.272) / 2157.533) / ((0 + 105.601) / 2275.6)
=0.035815 / 0.046406
=0.7718

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-937.373 - 0 - -888.109) / 2157.533
=-0.022833

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Medrx Co has a M-score of -2.70 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.70 mean?
Medrx Co (TSE:4586) has a Beneish M-Score of -2.70 as of Jul. 15, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Medrx Co and its competitors. According to the industry distribution chart, Medrx Co ranks #291 out of 911 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is Medrx Co's Beneish M-Score too high?
Medrx Co's current Beneish M-Score is -2.70. Based on the distribution chart, Medrx Co ranks #291 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medrx Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #291 out of 911 companies for Beneish M-Score. This puts Medrx Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Medrx Co and its competitors. Medrx Co's current Beneish M-Score is -2.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Modestly Undervalued. The stock's GF Value™ is 円70.55, compared to a current price of 円57.00 — trading 19.2% below its estimated fair value. The current Beneish M-Score is -2.70. Medrx Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current Beneish M-Score is -2.70 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medrx Co (TSE:4586) Overvalued in 2026?

Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued. The current stock price of 円57.00 is trading 19.2% below its estimated GF Value™ of 円70.55. GuruFocus considers Medrx Co to be Modestly Undervalued.

Key valuation signals for TSE:4586:

  • Beneish M-Score: -2.70
  • GF Value™: 円70.55 vs. price of 円57.00 (19.2% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medrx Co Business Description

Address 431-7 Nishiyama, Higashikagawa, Kagawa, JPN, 769-2712
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
57GF Score

Get the complete analysis for TSE:4586

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円57.00
Price
円70.55
GF Value